Nationally Recognized Medical Oncologist Will Lead Efforts to Further Strengthen ConcertAI’s Coordination with the Oncology Community and Focus on Patient-Centered Innovation
ConcertAI, a leading provider of oncology-focused AI SaaS and multi-modal data solutions for the healthcare and life sciences sectors, has appointed Dr. Shaalan Beg as its Chief Medical Officer for Oncology. In this new role, Dr. Beg will focus on deepening the company’s clinical engagement by expanding and strengthening the CancerLinQ community. He will act as a bridge between practicing oncologists and ConcertAI’s product development teams, ensuring that evolving clinical needs are translated into innovative and relevant solutions across the company’s offerings.
Health Technology Insights: Cycle Pharmaceuticals Launches PHYRAGO Tablets in US for Oncology
As Chief Medical Officer, Oncology, Dr. Beg will lead initiatives that support collaboration between clinicians and ConcertAI’s internal teams. He will facilitate advisory boards, working groups and clinician user forums that gather feedback from oncology professionals. These efforts aim to enhance communication and build a shared understanding of the clinical challenges oncologists face. Dr. Beg’s role also includes providing expert guidance on how real-world data and AI tools can be used more effectively to support cancer treatment decisions and improve outcomes for patients.
Health Technology Insights: Color Health, Google Cloud Team Up to Boost Breast Cancer Screening
Eron Kelly, CEO of ConcertAI, highlighted the strategic importance of Dr. Beg’s appointment. He noted that Dr. Beg’s background with the American Society of Clinical Oncology and his experience working with real-world data platforms uniquely qualify him to strengthen the company’s clinical partnerships. Kelly emphasized that Dr. Beg will play a key role in ensuring the perspectives of practicing oncologists are reflected in ConcertAI’s product strategy and innovation, keeping patient-centered care at the forefront of the company’s mission.
Dr. Beg is a respected oncologist and healthcare leader with expertise in gastrointestinal cancers, digital health and clinical research. He has held senior roles at the National Cancer Institute, where he contributed to national initiatives in clinical trial modernization and public-private collaborations. His academic and industry experience includes leadership positions at UT Southwestern Medical Center and Science37. He has authored work in several major medical journals, such as The New England Journal of Medicine, JAMA Oncology and the Journal of Clinical Oncology. In addition to his research, Dr. Beg has been an advisor to a number of influential organizations, including the White House Cancer Moonshot, CancerX and the Coalition for Healthcare AI. His contributions to the field have earned him a Fellow designation from the American Society of Clinical Oncology.
Dr. Beg shared his enthusiasm for the role, stating that he is eager to help ConcertAI advance its mission of using artificial intelligence to improve cancer care and research. Drawing from his experience in both clinical practice and healthcare innovation, he said he looks forward to helping the company develop solutions that meet the real-world needs of both life science organizations and care providers.
Health Technology Insights: IntrinsiQ Enhances Data Tools to Boost Patient Outcomes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
